EUCTR2011-002267-26-AT进行中（未招募）1 期
Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and glucose tolerance. An open label trial.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent
- •- Prior renal transplantation with a current tacrolimus-based immunosuppressive regimen
- •- Hepatitis C-infection
- •- Age 18-70 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 45
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •- Current hemodialysis or peritoneal dialysis
- •- Pregnancy or breastfeeding
- •- Known CsA-intolerance
研究者
相似试验
终止
3 期
MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C PositiveDe Novo Kidney TransplantNCT00284921Novartis Pharmaceuticals60
已完成
3 期
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver TransplantationHepatitis C Recurrence After Liver TransplantNCT01707849Hospital Vall d'Hebron18
招募中
不适用
Occult Hepatitis C virus in the liver-transplanted patients received anti-HCV therapyHepatitis C virus infectionJPRN-UMIN000026117Department of Gastroenterology and Hepatology, Nagasaki University Hospital70
已完成
不适用
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 BHepatitis CNCT01429155Henry Ford Health System36
Unknown
4 期
Hepatitis C in Renal Transplant RecipientsChronic Hepatitis C-virus InfectionRenal TransplantationNCT02108301Prof. Dr. Alice Schmidt30